<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250525065886N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-05-26</date_registration>
      <primary_sponsor>Riphah International University, Gulberg Green Campus, Gulberg-III, Lahore, Punjab, Pakistan</primary_sponsor>
      <public_title>Alfredson and Silbernagel exercises in athletes with Achilles tendinopathy</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Alfredson and Silbernagel exercise therapy on pain, range of motion, and muscle performance among athletes with Achilles tendinopathy.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83801</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly assigned to two groups using the sealed envelope method to ensure allocation concealment and reduce bias. A set of numbered envelopes will be prepared, each containing a predetermined treatment assignment. Upon obtaining patient consent, Group A will receive Alfredson exercises, while Group B will follow the Silbernagel exercise protocol, Blinding description: Blinding in this study means that participants will not be told which treatment group they are in or what treatment they will get. This will be done using the sealed envelope method so it will be a single-blind study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Achilles Tendinopathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group A – Alfredson Protocol. After basic stretching and mobility exercises, participants performed a 12-week eccentric training program, twice daily. It includes 4 exercises targeting Achilles tendinopathy: Weeks 1–2: Straight-knee eccentric heel drops (3×15, twice daily)Weeks 2–6: Bent-knee eccentric heel drops (3×15, twice daily)Weeks 6–8: Isometric holds during heel raises (30–45 sec hold, twice daily)Weeks 8–12: Calf raises (3×15–20, twice daily) Progression is achieved by adding 5 kg load when tolerated. Intervention 2: Intervention group: Group B – Silbernagel Protocol. After the same basic intervention, participants followed a 12-week combined loading program, once daily, focusing on concentric, eccentric, and plyometric exercises: Weeks 1–2: Isometric heel raises (45 sec hold × 5 reps) Weeks 2–6: Concentric + eccentric heel raises (3×15) Weeks 6–12: Plyometric hopping exercises (3×10) and sport-specific drills. Progression is also achieved by adding 5 kg load as tolerated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
yet to be decided, as the study will be complete in next 3 months

When:
yet to be decided, as the study will be complete in next 3 months

To whom:
To all the researchers community and clinicians

Conditions:
For research purposes and evidence-based practice in clinics

Where to obtain:
Google Scholar and PubMed

How to obtain:
Nil

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Laiba Rizwan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>25 Raza Saeed Road, Bhabra Block M Gulberg III, Lahore Punjab</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 343 7251576</telephone>
        <email>l.rizwann2@gmail.com</email>
        <affiliation>Riphah International University, Gulberg Green Campus, Gulberg-III, Lahore, Punjab, Pakistan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Laiba Rizwan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>25 Raza Saeed Road, Bhabra Block M Gulberg III, Lahore Punjab</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 343 7251576</telephone>
        <email>l.rizwann2@gmail.com</email>
        <affiliation>Riphah International University, Gulberg Green Campus, Gulberg-III, Lahore, Punjab, Pakistan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Both male and female athletes
Age between 18 to 30 years
Duration of playing at least 1 to 2 years
Athletes with chronic Achilles tendinopathy for more than 3 months
Participating in sports involving Achilles tendon loading (i.e., sports characterized by walking, running, and/or jumping)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Corticosteroid injections in the region of the Achilles tendon in the previous 12 months
Any neurological disease
History of fracture
Players having any co-morbidities
Athletes have systemic diseases that can hinder training
Any surgery in the lower limb region in the past two years</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group A – Alfredson Protocol. After basic stretching and mobility exercises, participants performed a 12-week eccentric training program, twice daily. It includes 4 exercises targeting Achilles tendinopathy: Weeks 1–2: Straight-knee eccentric heel drops (3×15, twice daily)Weeks 2–6: Bent-knee eccentric heel drops (3×15, twice daily)Weeks 6–8: Isometric holds during heel raises (30–45 sec hold, twice daily)Weeks 8–12: Calf raises (3×15–20, twice daily) Progression is achieved by adding 5 kg load when tolerated.</i_keyword>
      <i_keyword>Intervention group: Group B – Silbernagel Protocol. After the same basic intervention, participants followed a 12-week combined loading program, once daily, focusing on concentric, eccentric, and plyometric exercises: Weeks 1–2: Isometric heel raises (45 sec hold × 5 reps) Weeks 2–6: Concentric + eccentric heel raises (3×15) Weeks 6–12: Plyometric hopping exercises (3×10) and sport-specific drills. Progression is also achieved by adding 5 kg load as tolerated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Range of motion and Muscle performance. Timepoint: Baseline and after 12 weeks. Method of measurement: NPRS, Goniometry, Calf Raise Test, Hop Test, VISA-A Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Riphah International University, Gulberg Green Campus, Gulberg-III, Lahore, Punjab, Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-30</approval_date>
        <contact_name>Ethics Committee of Riphah College of Rehabilitation and Allied Health Sciences</contact_name>
        <contact_address>26-M Gulberg-3 Campus Lahore Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
